Skip to main content
. Author manuscript; available in PMC: 2025 Mar 10.
Published in final edited form as: J Am Med Dir Assoc. 2025 Jan 18;26(3):105440. doi: 10.1016/j.jamda.2024.105440

Table 3.

Characteristics of Residents With New-Onset ICD-10-CM Diagnoses for COVID-19 and PPV of Diagnosis Codes, Identified in the EHR Problem List (n = 3685) for Residents Continuously Present in the Nursing Home for at Least 3 Days Before and After the Diagnosis Onset Date, Stratified by the Presence of Corresponding Positive Test Within 7 Days

Characteristic Corresponding Positive
Test Within 7 Days
No Corresponding Positive Test
Within 7 Days
χ2 P Value PPV
n (col %) n (col %) Estimate
(95% CI)
Overall 3395 290 92% (91%–93%)
Date of onset
 Jan–Mar 2022 1210 (36) 99 (34) <.0001 92% (91%–94%)
 Apr–Jun 2022 255 (8) 10 (3) 96% (94%–99%)
 July–Sep 2022 782 (23) 18 (6) 98% (97%–99%)
 Oct–Dec 2022 555 (16) 76 (26) 88% (85%–91%)
 Jan–Mar 2023 478 (14) 68 (23) 88% (85%–90%)
 Apr–Jun 2023 115 (3) 19 (7) 86% (79%–92%)
Resident characteristics
 Sex
  Male 1245 (37) 99 (34) .4128 93% (91%–94%)
  Female 2150 (63) 190 (66) 92% (91%–93%)
 Age, y
  <65 483 (14) 45 (16) .4564 91% (89%–94%)
  65–74 822 (24) 75 (26) 92% (90%–94%)
  75–84 1104 (33) 81 (28) 93% (92%–95%)
  >85 986 (29) 89 (31) 92% (90%–93%)
 Resident length of stay in the study period
  Short stay (≤90 d) 881 (26) 70 (24) .4985 93% (91%–94%)
  Long stay (>90 d) 2514 (74) 220 (76) 92% (91%–93%)
 Previous COVID-19 diagnosis or positive
   SARS-CoV-2 test
  15–90 d prior 3 (0.09) 17 (6) <.0001 15% (0%–55%)
  90–180 d prior 54 (2) 4 (1) 93% (86%–100%)
  >180 d prior 737 (22) 64 (22) 92% (90%–94%)
  First listed 2601 (77) 205 (71) 93% (92%–94%)
 Number of comorbidities*
  None 1590 (47) 148 (51) .0760 91% (90%–93%)
  1–2 1152 (34) 94 (32) 92% (91%–94%)
  3–4 587 (17) 38 (13) 94% (92%–96%)
  5–6 66 (2) 10 (3) 87% (79%–95%)

Data are shown for incident-positive tests; a resident’s characteristics may be included more than once if they had multiple incident-positive tests; P values are for χ2 tests assessing differences between characteristics and presence of a corresponding positive test.

*

Comorbidities assessed include cancer, chronic kidney disease, chronic obstructive pulmonary disease, heart conditions, immunocompromised state, chemotherapy, radiation, obesity, sickle cell disease, smoking, and diabetes.